STING Gain-of-Function Disrupts Lymph Node Organogenesis and Innate Lymphoid Cell Development in Mice

STING功能获得性突变会破坏小鼠淋巴结器官发生和先天性淋巴细胞发育

阅读:3
作者:Brock G Bennion ,Carys A Croft ,Teresa L Ai ,Wei Qian ,Amber M Menos ,Cathrine A Miner ,Marie-Louis Frémond ,Jean-Marc Doisne ,Prabhakar S Andhey ,Derek J Platt ,Jennifer K Bando ,Erin R Wang ,Hella Luksch ,Thierry J Molina ,Elisha D O Roberson ,Maxim N Artyomov ,Angela Rösen-Wolff ,Marco Colonna ,Frédéric Rieux-Laucat ,James P Di Santo ,Bénédicte Neven ,Jonathan J Miner

Abstract

STING gain-of-function causes autoimmunity and immunodeficiency in mice and STING-associated vasculopathy with onset in infancy (SAVI) in humans. Here, we report that STING gain-of-function in mice prevents development of lymph nodes and Peyer's patches. We show that the absence of secondary lymphoid organs is associated with diminished numbers of innate lymphoid cells (ILCs), including lymphoid tissue inducer (LTi) cells. Although wild-type (WT) α4β7+ progenitors differentiate efficiently into LTi cells, STING gain-of-function progenitors do not. Furthermore, STING gain-of-function impairs development of all types of ILCs. Patients with STING gain-of-function mutations have fewer ILCs, although they still have lymph nodes. In mice, expression of the STING mutant in RORγT-positive lineages prevents development of lymph nodes and reduces numbers of LTi cells. RORγT lineage-specific expression of STING gain-of-function also causes lung disease. Since RORγT is expressed exclusively in LTi cells during fetal development, our findings suggest that STING gain-of-function prevents lymph node organogenesis by reducing LTi cell numbers in mice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。